bluuebunny/crossref_metadata_2025_split huggingface dataset:
Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors
Authors: Warren Katherine E. , Aikin Alberta A. , Libucha Madeleine , Widemann Brigitte C. , Fox Elizabeth , Packer Roger J. , Balis Frank M. 
Published: October 2005

Purpose This pediatric phase I trial of O6-benzylguanine (O6BG) and temozolomide (TMZ) on a daily schedule for 5 days, every 28 days was performed to determine the maximum-tolerated dose of TMZ when given with a biologically active dose of O6BG and to define the toxicity profile of the combination in children with solid tumors. Patients and Methods Patients ≤ 21 years old with refractory solid tumors were eligible. O6BG was administered intravenously over 60 minutes daily for 5 days. TMZ was administered orally 30 minutes after completion of each O6BG infusion. Starting doses of O6BG and TMZ were 60 mg/m2/d and 28 mg/m2/d, respectively. O6BG was escalated to 90 and 120 mg/m2/d; TMZ was subsequently escalated to 40, 55, 75, and 100 mg/m2/d. Cycles were repeated every 28 days. Results Forty-one patients were enrolled; 32 patients were assessable for toxicity. The combination of O6BG and TMZ was tolerable at TMZ doses less than half of the conventional dose of 200 mg/m2/d. Myelosuppression occurred sporadically at all dose levels and was the dose-limiting toxicity (DLT) at 100 mg/m2/d of TMZ combined with 120 mg/m2/d O6BG. Nonhematologic toxicities were generally mild. Evidence of antitumor activity was observed at 120 mg/m2/d O6BG combined with TMZ doses of 55 mg/m2/d and above. Conclusion The recommended doses of O6BG administered with TMZ on a 5-day schedule in children are 120 mg/m2/d of O6BG and 75 mg/m2/d of TMZ. Evidence of activity was observed at these doses. Myelosuppression was the DLT.
Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies
Authors: Ascierto Paolo A. , Scala Stefania , Castello Giuseppe , Daponte Antonio , Simeone Ester , Ottaiano Alessandro , Beneduce Gerardo , De Rosa Vincenzo , Izzo Francesco , Melucci Maria Teresa , Ensor C. Mark , Prestayko Archie W. , Holtsberg Frederick W. , Bomalaski John S. , Clark Mike A. , Savaraj Niramol , Feun Lynn G. , Logan Theodore F. 
Published: October 2005

PurposeIndividuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid–degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma.Patients and MethodsTwo cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw.ResultsPK and PD studies indicated that a dose of 160 U/m2lowered plasma arginine from a resting level of approximately 130 μmol/L to less than 2 μmol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival.ConclusionElimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.
Multifocal and Multicentric Breast Cancer: Does Each Focus Matter?
Authors: Coombs Nathan J. , Boyages John 
Published: October 2005

Purpose The identification of multiple tumors in the breast is associated with increased nodal involvement when compared with similar staged unifocal disease. This study compares two methods of tumor size assessment to predict tumor behavior in the relationship between size and axillary node involvement for patients with multifocal and multicentric breast cancer. Methods The histologic reports of every patient with multifocal breast cancer treated in New South Wales between April 1995 and September 1995 were examined. Tumors were assessed using two size estimates: (1) largest tumor focus diameter and (2) the aggregate diameters of all tumor foci. The dimensions were compared with unifocal tumors and against node positivity. Results Ninety-four (11.1%) of 848 women had multifocal breast cancer and of these 49 women (52.1%) had axillary node involvement compared with 37.5% with unifocal breast cancer (P =.007). The use of aggregate dimension reclassified significant numbers of multifocal tumors at a more advanced stage. Use of this method to stage cancers, rather than the largest tumor size, removed the excess node positivity when compared with unifocal, stage-matched breast carcinomas. Conclusion The tendency of breast tumors to metastasize is a reflection of the total tumor load. Failure to measure the additional tumor burden provided by multiple small foci may understage a woman's disease. This may deny patients the opportunity of adjuvant therapies if the contribution of the smaller foci to the incidence of node positivity and survival is ignored.
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Authors: Fisher Richard I. , LeBlanc Michael , Press Oliver W. , Maloney David G. , Unger Joseph M. , Miller Thomas P. 
Published: October 2005

Background The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable. However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown. Patients and Methods In the current analysis, we identified all previously untreated, advanced-stage, follicular lymphoma patients treated with the following three sequential treatment approaches: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy ± nonspecific immunostimulants (Southwest Oncology Group [SWOG] 7426 and 7713: 1974 to 1983); prednisone, methotrexate, doxorubicin, cyclophosphamide, and etoposide (ProMACE) plus mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) ± interferon (SWOG 8809: 1988 to 1994); and CHOP followed by monoclonal antibody (MoAb) therapy (SWOG 9800 and 9911: 1998 to 2000). We assessed the patients' progression-free survival (PFS) and overall survival (OS). The MoAb trials included CHOP followed by rituximab (SWOG 9800) and CHOP followed by 131I-tositumomab (SWOG 9911). Results The PFS curves for the CHOP and ProMACE-MOPP studies are overlapping, with 4-year PFS estimates of 46% and 48%, respectively. However, the PFS rate of the CHOP + MoAb studies is significantly improved at 61% (P = .005). The OS curves show improvement with each succeeding study. The 4-year estimate of OS is 69% for the CHOP regimens, 79% for the ProMACE-MOPP study, and 91% for the CHOP + MoAb regimens (P < .001). These conclusions were retained after adjusting for differences in prognostic factors between the study groups. Conclusion The results of this study suggest that OS for patients with follicular lymphoma has improved over time and that the choice of initial therapy may matter.
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
Authors: Alberts Steven R. , Horvath William L. , Sternfeld William C. , Goldberg Richard M. , Mahoney Michelle R. , Dakhil Shaker R. , Levitt Ralph , Rowland Kendrith , Nair Suresh , Sargent Daniel J. , Donohue John H. 
Published: October 2005

Purpose Surgical resection of liver-only metastases from colorectal cancer has undergone extensive evaluation and review. The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied. Patients and Methods Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4). Patients were periodically reassessed for resectability. Surgical response was classified as completely resectable (S-CR), partially resectable (S-PR), or unresectable (S-UR). Study design specified the accrual of 39 patients, with two or more S-CRs considered evidence of promising activity with respect to increasing the S-CR rate. Results Forty-two of 44 patients were assessable for this analysis. Twenty-five patients (60%) had tumor reduction by serial imaging. Seventeen patients (40%) underwent surgery (S-CR, n = 14; S-PR, n = 1; and S-UR, n = 2) after a median of 6 months of chemotherapy. With a median postsurgical follow-up of 22 months (range, 13 to 32 months), 11 recurrences have occurred in the 15 S-CR and S-PR patients. Median survival time was 26 months. Conclusion Our data suggest that FOLFOX4 has a high response rate (complete response, partial response, or reduction) in patients with liver-only metastases from colorectal cancer, allowing for successful resection of disease in a portion of patients initially not judged to be optimally resectable. However, a high recurrence rate after surgery was observed, which, in 73% of patients, involved the liver. Further trials are indicated based on the promising results observed in this trial.
Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group
Authors: Behringer Karolin , Breuer Kai , Reineke Thorsten , May Michael , Nogova Lucia , Klimm Beate , Schmitz Tatiana , Wildt Ludwig , Diehl Volker , Engert Andreas 
Published: October 2005

Purpose Long-term survivors of successfully treated Hodgkin’s lymphoma (HL) are at risk for late complications. Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy. Patients and Methods From 1994 to 1998, the German Hodgkin’s Lymphoma Study Group conducted clinical trials for early-, intermediate-, and advanced-stage HL (trials HD7 to HD9) involving a total of 3,186 patients. A survey was carried out to evaluate the menstrual status after therapy. The following factors were assessed concerning their influence on amenorrhea: age, treatment, stage, and the use of oral contraceptives during chemotherapy. Results A total of 405 women aged younger than 40 years answered the study questions. After a median follow-up of 3.2 years, 51.4% of the women receiving eight cycles of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) had continuous amenorrhea. Amenorrhea was significantly more frequent after dose-escalated BEACOPP compared with doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .0066). Amenorrhea after therapy was most pronounced in women with advanced-stage HL (P < .0001), in women older than 30 years at treatment (P = .0065), and in women who did not take oral contraceptives during chemotherapy (P = .0002). Conclusion Most women who are treated for advanced-stage HL experience amenorrhea after therapy. Amenorrhea is significantly more frequent in women with advanced-stage HL receiving eight cycles of dose-escalated BEACOPP and in women older than 30 years at first treatment. Furthermore, the data show a statistical association between the use of oral contraceptives and return of menstrual cycle, which is subject to further investigation.
Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children’s Cancer Group
Authors: Geyer J. Russell , Sposto Richard , Jennings Mark , Boyett James M. , Axtell Richard A. , Breiger David , Broxson Emmett , Donahue Bernadine , Finlay Jonathan L. , Goldwein Joel W. , Heier Linda A. , Johnson Dennis , Mazewski Claire , Miller Douglas C. , Packer Roger , Puccetti Diane , Radcliffe Jerilynn , Tao May Lin , Shiminski-Maher Tania 
Published: October 2005

Purpose To evaluate response rate, event-free survival (EFS), and toxicity of two chemotherapeutic regimens for treatment of children younger than 36 months with malignant brain tumors and to estimate control intervals without irradiation in children with no residual tumor after initial surgery and induction chemotherapy and with delayed irradiation in patients with residual tumor or metastatic disease at diagnosis. Patients and Methods Patients were randomly assigned to one of two regimens of induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide v vincristine, carboplatin, ifosfamide, and etoposide). Maintenance chemotherapy began after induction in children without progressive disease. Children with no residual tumors after induction therapy and no metastatic disease at diagnosis were not to receive radiation therapy unless their tumors progressed. Results Two hundred ninety-nine infants were enrolled. Forty-two percent of patients responded to induction chemotherapy. At 5 years from study entry, the EFS rate was 27% ± 3%, and the survival rate was 43% ± 3%. There was no significant difference between the two arms in terms of response rate or EFS. For medulloblastoma, supratentorial primitive neuroectodermal tumor, ependymoma, and rhabdoid tumors, 5-year EFS rates were 32% ± 5%, 17% ± 6%, and 32% ± 6%, and 14% ± 7%, respectively. Fifty-eight percent of patients who were alive 5 years after study entry had not received radiation therapy. Conclusion Intensified induction chemotherapy resulted in a high response rate of malignant brain tumors in infants. Survival was comparable to that of previous studies, and most patients who survived did not receive radiation therapy.
Binuclear complexes as tectons in designing supramolecular solid-state architectures
Authors: Andruh Marius 
Published: October 2005

Abstract
Oligonuclear complexes as well as coordination polymers with various network topologies can be obtained by using homo- or heterobinuclear complexes as starting materials. These building blocks are stable complexes, where the metal ions are held together by compartmental ligands, or alkoxo-bridged Cu(II) species. The binuclear nodes can be connected through appropriate exo-dentate ligands, or through metal-containing anions (e.g., [M(CN)6]3-, M = CrIII, FeIII, CoIII). A rich variety of 3d-3d and 3d-4f heterometallic complexes, with interesting architectures and topologies of the spin carriers, has been obtained. A particular case is the one concerning the 3d-4f binuclear nodes. Following this strategy, we were able to obtain coordination polymers containing three different spin carriers (2p-3d-4f; 3d-3d'-4f).
Photodegradation of pesticides and application of bioanalytical methods for their detection
Authors: Franko Mladen , Sarakha Mohamed , Čibej Anja , Boškin Aleš , Bavcon Mojca , Trebše Polonca 
Published: October 2005

Abstract
Photodegradation of coumaphos and azinphos-methyl in the air, in oxygen, and in nitrogen atmosphere (quartz reactor equipped with six 18-W lamps with the maximum emission intensity at 310 nm) was studied. The fastest reaction occurred with coumaphos in nitrogen atmosphere (complete decomposition in 10 min), where the formation of a new compound was also detected by high-performance liquid chromatography (HPLC). In the case of azinphos-methyl, no additional signals in HPLC chromatogram were observed. The rearrangement mechanism, involving a triplet-state activation complex and the formation of an acetylcholinesterase (AChE)-inhibiting oxo analog of coumaphos was verified and confirmed by laser flash photolysis.
The suitability of bioanalytical flow-injection analysis (FIA) systems, based on AChE inhibition and spectrophotometric or thermal lens spectrometric detection for rapid and sensitive screening in food quality control was demonstrated. Owing to the high sensitivity of thermal lens spectrometry (TLS), several steps in sample preparation can be avoided (preconcentration, purification, isolation) and incubation times reduced. High sample throughputs (10 h-1) are, however, also achievable for medium toxic oxo organophosphorus (OP) pesticides using spectrophotometric detection providing limits of detection (LODs) at the level of 10 ppb malaoxon equivalents, which is still about 50 times below maximal residue levels. Testing of the method for practical application on a set of 60 samples gave no false negative results and a level of 1.7 % false positives.
Hazardous industrial waste stabilization using inorganic phosphates: Investigation of possible mechanisms
Authors: Ioannidis Themistoklis A. , Zouboulis Anastasios I. 
Published: October 2005

Abstract
The present study focuses on the use of phosphate-containing compounds, such as apatites, as stabilization additives for solid industrial wastes. The examined highly toxic waste contained mainly lead, iron, and bromides. Phosphates (synthetic or natural), when used as additives, were found to diminish the release of lead from the stabilized waste below the respective legislative concentration limits, following the application of DIN 38414 standard leaching method and within the range of pH values 7.5-10.5. The respective synthetic compounds of lead, PbO and Pb(OH)Br, existing also in the solid waste, were additionally studied during simulation experiments, in order to examine the possible mechanisms of waste stabilization, by using the same additives (phosphates). The obtained results showed the possibility of another parallel mechanism, different from that proposed in the literature, which is the sorption of aqueous lead ions onto the apatite surface. It was suggested that lead can be also transformed into the less soluble solid phases through the interaction (surface crystallization) of exposed lead surface with the aqueous environment. The formation of new crystals onto the surface of lead phase was sufficiently fast, especially in the case of natural phosphate mineral additive, most probably due to the presence of calcite, which supplies part of its carbonate content for the formation of respective lead carbonate solid phases.
A Web‐based Tool for UV lrradiance Data: Predictions for European and Southeast Asian Sites
Authors: Kift Richard , Webb Ann R. , Page John , Rimmer John , Janjai Serm 
Published: October 2005

ABSTRACTThere are a range of UV models available, but one needs significant pre‐existing knowledge and experience in order to be able to use them. In this article a comparatively simple Web‐based model developed for the SoDa (Integration and Exploitation of Networked Solar Radiation Databases for Environment Monitoring) project is presented. This is a clear‐sky model with modifications for cloud effects. To determine if the model produces realistic UV data the output is compared with 1 year sets of hourly measurements at sites in the United Kingdom and Thailand. The accuracy of the output depends on the input, but reasonable results were obtained with the use of the default database inputs and improved when pyranometer instead of modeled data provided the global radiation input needed to estimate the UV. The average modeled values of UV for the UK site were found to be within 10% of measurements. For the tropical sites in Thailand the average modeled values were within 1120% of measurements for the four sites with the use of the default SoDa database values. These results improved when pyranometer data and TOMS ozone data from 2002 replaced the standard SoDa database values, reducing the error range for all four sites to less than 15%.
Potentiation of the Antitumor Effect of Merocyanine 540‐mediated Photodynamic Therapy by Amifostine and Amphotericin B
Authors: Tsujino Ichiro , Miyagi Kiyoko , Sampson Reynée W. , Sieber Fritz 
Published: October 2005

ABSTRACTLeukemia and lymphoma cells are much more sensitive to Merocyanine 540 (MCS40)‐mediated photodynamic therapy (PDT) than normal pluripotent hematopoietic stem cells and normal colony forming unit‐granulocyte/macrophage progenitors (CFU‐GM). By contrast, most solid tumor cells are only moderately sensitive to MC540‐PDT. The limited activity against solid tumor cells has detracted from MC540's appeal as a broad‐spectrum purging agent. We report here that noncytotoxic concentrations of amifostine (Ethyol, Ethiofos, WR‐2721) and amphotericin B used either alone or in combination potentiate the MC540‐sensitized photoinactiva‐tion of leukemia cells, wild‐type small cell lung cancer cells and cisplatin‐resistant small cell lung cancer cells. Amphotericin B also enhances the MC540‐sensitized photoinactivation of normal CFU‐GM, whereas amifostine protects CFU‐GM against the cytotoxic action of MC540‐PDT. The yield of CD34‐positive normal hematopoietic stem and progenitor cells is only minimally diminished by pretreatment with amifostine, amphotericin B or combinations of amifostine plus amphotericin B. Purging protocols that combine MC540‐PDT with amifostine or with amifostine plus amphotericin B could offer a simple and effective approach to the purging of autologous stem cell grafts that are contaminated with solid tumor cells or the purging of stem cell grafts from heavily pretreated leukemia patients that contain reduced numbers of normal stem and progenitor cells and, therefore, can ill afford additional losses caused by purging.
Structure and properties of thermoplastic corn starch/montmorillonite biodegradable composites
Authors: Huang Mingfu , Yu Jiugao 
Published: October 2005

Abstract“Green” composites were successfully prepared from the thermoplastic cornstarch (TPCS) and activated‐montmorillonite (MMT) by the method of blend extrusion. The thermoplastic cornstarch was plasticized with novel plasticizers urea and ethanolamine, and the activated‐montmorillonites were obtained using ethanolamine as the activated solvent. The structure and morphology of “Green” composites were characterized by wide‐angle X‐ray diffraction (WAXD), scanning electron microscope (SEM), and transmission electron microscope (TEM). SEM and TEM images indicated that the composites presented reticulating fiber structure after being cooled by liquid nitrogen. The exfoliated MMT sheets in the composites acted as the inhomogeneous nucleation effect. The melting urea was crystaled over on the MMT sheets in the inducement of ethanolamine, and the column‐shape crystal whisker overlapped together. Comparing with normal temperature, the mechanical properties of composites evidently improved after being cooled by liquid nitrogen, which was proved by the mechanical testing. The thermal stability and water‐resistance of the composites also were studied in this paper. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci 99: 170–176, 2006